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age, with a peak incidence in the age range of 25-30 years 
(1). Women with endometriosis frequently experience symp-
toms of dysmenorrhea, dyspareunia and chronic fatigue (2), 
and it may interfere with the functioning of their bowel or 
bladder, depending on the site where endometriotic lesions 
develop (3); up to 50% experience infertility (4). An impact 
on many aspects of a woman’s life including work, educa-
tion, relationships and social functioning has been described 
(5-11). Because of the chronicity of the disease, several pa-
tients have a negative impact on neuroendocrine function 
and mental health, showing stress, depression and anxiety 
(12). The severity of these symptoms is correlated with the 
intensity of pain. As symptoms become more severe, quality 
of life is reduced, and women with endometriosis refer to a 
substantial 38% reduction in work productivity, 30% in family 
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Introduction
Endometriosis is a chronic estrogen-dependent disease 
that affects approximately 10% of women of reproductive 
AbSTRACT
background: The aim of this study was to assess the efficacy of dienogest treatment in improving quality of life 
in women with endometriosis.
Methods: This was a prospective observational multicenter study at the universities of Siena, Milano, Cagliari, 
Perugia, Busto Arstizio, Pisa, Padova, Palermo, Foggia, Roma, Pescara and Catanzaro, including 142 patients with a 
diagnosis of endometriosis who received dienogest 2 mg once daily, for up to 90 days. Each patient underwent an 
evaluation of pelvic pain measured by visual analogue scale (VAS) from 0 to 10 points, and of quality of life measured 
by a mental and physical index before and after treatment.
Results: The mean ± SD of VAS was 8.2 ± 1.6 in women with endometriosis, and this progressively and signifi-
cantly decreased to 5.9 ± 2.6 at the end of the study. Mental index score values increased from 39.0 ± 9.8 to 46.0 ± 
9.1 (p<0.001); likewise, the physical index increased from 39.6 ± 9.6 to 47.7 ± 8.5 (p<0.001). During the treatment 
period, the most frequent adverse events (AEs) were headache (30.8%), followed by bleeding (29.4%), depres-
sion (26.6%), breast tenderness (23.8%) and acne (2.0%), but these were transitory, and none led to withdrawal 
from the study.
Conclusions: The present prospective study showed that dienogest is an effective and well-tolerated treatment 
improving the quality of life in endometriotic women.
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and social life and in their sports activities, attributable pri-
marily to the presence of related pain (13, 14).
Effective long-term management of endometriosis is a 
significant clinical objective in view of the debilitating na-
ture of this chronic condition. Among current management 
approaches, surgery and hormonal drugs are considered as 
primary treatment or to reduce the recurrences.
The current cure for endometriosis is surgical and/or med-
ical. Surgery is a common treatment choice, but recurrence 
rates are high: approximately 40%-50% after 5 years (15, 16). 
Approved medical treatments for relief of the symptoms of 
endometriosis include gonadotropin-releasing hormone 
(GnRH) analogs and danazol. Both of these classes of treat-
ment may be used as primary treatment and after surgery. 
However, both drugs are associated with suboptimal safety 
and tolerability that limit their long-term use (17). A number 
of progestins offer long-term efficacy but, depending on their 
pharmacologic profile, can cause weight gain or androgenic 
effects at the high doses required for efficacy (18).
Dienogest offers unique pharmacological targets relevant 
to the treatment of endometriosis, including potent proges-
togenic effects that lead to effective endometrial lesion re-
duction, combined with moderate suppression of estrogen 
levels (19) and reduction of inflammatory mechanisms (20) 
and of angiogenesis (21).
Dienogest treatment for periods of 12-24 weeks has been 
reported to be superior in efficacy in comparison with pla-
cebo (22) and equivalent to leuprolide acetate and busere-
lin acetate (23, 24). Long-term studies (22, 25, 26) have also 
revealed a decrease of endometriosis-associated pain, with 
limited adverse events (mostly mild or moderate in intensity), 
associated with low discontinuation rates.
The present prospective study aimed to evaluate the 
effect of dienogest on quality of life during treatment for 
endometriosis.
Materials and methods
The present prospective, observational, multicenter, co-
hort study aimed to evaluate quality of life in endometriotic 
women treated with dienogest.
Women were eligible for the study if aged from 18 years, 
with diagnosis of endometriosis associated with visual ana-
logue scale (VAS) pelvic pain score from 0 to 10 cm at start of 
treatment, waiting for surgery or in patients with previous sur-
gery for endometriosis and recurrent pelvic pain (Tab. I). Exclu-
sion criteria were the simultaneous presence of uterine benign 
disorders such as uterine fibroids and endometrial polyps, and 
malignant uterine and ovarian pathologies. Recruitment was 
completed when the foreseen sample size in all participating 
centers (competitive recruitment) was reached. A group of 142 
patients was enrolled; with mean age of 34.9 years (SD = 6.5).
Dienogest (2 mg) was administered once daily, for up to 
90 days. At study entry, general characteristics and clinical in-
formation regarding diagnosis of endometriosis were collect-
ed. A VAS value was collected. Further, the patient was asked 
to fill out the Short Form 12 (SF-12; see below) quality-of-life 
questionnaire and to come back after 30 days (V1).
Quality of life was measured using the SF-12 question-
naire. This questionnaire is a well-known 12-item generic 
 quality-of-life measure that assesses physical and mental func-
tioning over the previous 4 weeks. Scores range from 0 to 100 
for each dimension, with 100 indicating optimal quality of life 
(27, 28). Baseline to V2 (90 days after study entry) differences 
in the VAS and SF-12 questionnaire score were computed.
At V1 (30 days), the patient was interviewed on their regu-
lar intake of dienogest and any clinical symptoms or adverse 
events (AEs), including bleeding. In case of discontinuation of 
dienogest treatment, reason for discontinuation was collected. 
Women were also requested to assess endometriosis-related 
pelvic pain using the VAS. The patient was also asked to con-
tinue the treatment and to come back again after 60 days (i.e., 
total of 90 days after study entry, V2). At V2, the patient was 
interviewed again on the regular intake of dienogest, clinical 
symptoms and AEs. She was also asked to assess VAS scale pel-
vic pain intensity and fill out the SF-12 questionnaire.
AEs were documented at all study visits and coded ac-
cording to the appropriate Medical Dictionary for Regulatory 
Activities primary system organ class. The use of any concom-
itant medications for pain was also recorded in all visits. The 
institutional review committees of the participating centers 
approved the study. All women signed an informed consent 
form.
Sample size
Literature data indicate that in patients with VAS aver-
age equal to 4, the expected average reduction of the value 
of VAS after treatment for 3 month with dienogest is 2.0, 
with standard deviation (SD) 2.0 (15). We foresaw including 
100 patients. With such a sample size, we would be able to 
evaluate a mean change from baseline VAS of 0.8 or greater 
(minimum reduction deemed significant from a clinical point 
of view), with SD = 2.0, at the usual levels of alpha (0.05) and 
beta (0.20). To make up for a possible dropout rate of about 
15%, the sample size was increased to 118.
Statistical analysis
Descriptive statistics – mean (SD), median (interquartile 
range [IQR]) and frequency (%) – were used to describe the 
study population. Baseline to V2 differences in the VAS and 
SF-12 questionnaire scores were computed, and the statisti-
cal significance of changes from baseline was evaluated by 
paired t-test.
TAbLE I - Distribution of study subjects at study entry
Total series (n = 142)
Age, years 34.9 ± 6.5
Time since diagnosis, years 4.5 ± 5.3
BMI (calculated as kg/m2) 21.6 ± 2.9
Waiting for surgery, no. (%) 72 (50.7)
Previous surgery for endometriosis, no. (%) 70 (49.3)
Values are means ± standard deviation, or number (%), as indicated.
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Results
Pain
Table II shows the distribution of study subjects at entry 
and follow-up visit according to VAS values. The mean ± SD VAS 
score at baseline was 8.0 ± 1.7 in the total series. The VAS score 
progressively and significantly decreased (p<0.01) to 5.2 ± 2.5 
at the end of the study (V2) in the total population (Tab. II).
Quality of life (SF-12 questionnaire)
The mean scores for physical and mental components of 
the SF-12 are shown in Table III. The mental index score val-
ues increased in the total series from 39.0 ± 9.8 to 46.0 ± 9.1 
(p<0.001). Likewise, the physical index increased from 39.6 ± 
9.6 to 47.7 ± 8.5 (p<0.001).
Adverse events
The most frequent AE was headache (30.8%), followed 
by bleeding (29.4%; for a median duration of 7 days, IQR 
4-20), depression (26.6%), breast tenderness (23.8%) and 
acne (2.0%). Mostly, AEs grade was described as moderate 
(47.7%), and the dropout rate of patients was 4%.
Discussion
The present study showed that dienogest is effective in 
increasing the quality of life in women with endometriosis. 
The impact of endometriosis on reducing the quality of life 
is substantial and wide ranging (6-14). Quality-of-life assess-
ments in the present study showed improvements in both 
physical and mental indices within 12 weeks, also confirming 
the decrease of endometriosis-associated pain (22-25).
Randomized clinical trials and clinical series have consis-
tently shown that dienogest is effective in the treatment of 
pain-related endometriosis (22-25). Our original finding is the 
analysis of the effect of dienogest on the mental and physical 
SF index scores values, which increased during the 3-month 
study period by about 15%. The painful chronic symptoms of 
endometriosis are known to be a causal factor of poor quality 
of life in endometriotic women, and various instruments (e.g., 
SF-36®, SF-12®, EQ-5D, Duke Health Profile) have been used to 
measure effects on quality of life and health-related problems 
in patients with endometriosis (29). Endometriosis significantly 
affects women and societies worldwide (30). Dyspareunia and 
chronic pain are 2 factors affecting both physical and mental 
components of quality of life. Awareness of these symptoms in 
primary care may lead in the future to earlier diagnosis, to less 
suffering and to improved work productivity (30).
Pain and reduced quality of life may also induce high lev-
els of perceived stress in women with the various forms of 
endometriosis and are correlated with the most severe form 
(deep infiltrating endometriosis) (31). Stress is reduced by 
surgical or medical treatment to relieve pain; the most ef-
fective approach to reducing stress is progestin long-term 
therapy (32).
An empirical dienogest treatment option for women 
without laparoscopic confirmation represents a suitable ad-
juvant therapy before undergoing surgery (33). An effective 
long-term management of endometriosis after surgery is a 
significant clinical objective in view of the debilitating na-
ture of this chronic condition. Among current management 
approaches, recurrence is common after surgery, and the 
search for a medical treatment is an important goal. A previ-
ous study has shown that oral contraception pills are useful 
in this direction in woman operated on for endometriosis 
(34). The present study suggests the use of dienogest for 
this purpose. The safety analysis of the study indicated an 
acceptable profile for dienogest in routine clinical practice. 
In fact, only 6 cases (4%) of interruption of treatment were 
permanent, which is similar or lower to the rates reported 
in previous randomized clinical trials. In particular, irregular 
bleeding was reported to be present for a mean 7 days over 
the 3-month study period.
Potential limitations of this study to be considered are the 
observational form and the lack of control group. This design 
TAbLE II - Pelvic pain at study entry and 90 days (V2)
Total series
Endometriosis-related pain
 Baseline 142
 V2 59 (41.6)
Painful days during the month before visit (mean)
 Baseline 17.0 (18.9)
 V2 8.8 (9.5)
VAS
 Baseline 8.0 (1.7)
 V2 5.2 (2.5)
Sick leave
 Baseline 87 (61.3)
 V2 8 (12.4)
Days off work
 Baseline 8.4 (10.7)
 V2 6.4 (5.5)
Painkillers
 Baseline 65 (45.8)
 V2 31 (21.8)
Values are means (standard deviation).
VAS = visual analogue scale.
TAbLE III - Results of the SF-12 questionnaire
baseline V2 p Value
Total series
SF-12 mental index 39.0 (9.8) 46.0 (9.1) <0.0001
SF-12 physical index 39.6 (9.6) 47.7 (8.5) <0.0001
Values are means (standard deviation).
V2 = at 90 days from start of treatment.
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was chosen to evaluate the use of dienogest in routine clinical 
practice, and perspective cases were consecutively identified 
in the participating centers.
In conclusion, this prospective study showed that dieno-
gest improves quality of life in women with endometriosis, 
supporting the possible use of this drug as primary or second-
ary treatment for endometriosis.
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